{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:33:18Z","timestamp":1793363598798,"version":"4.5.0"},"reference-count":26,"publisher":"BMJ","issue":"1","funder":[{"name":"R\u00e9gion Ile-de-France","award":["Doctoral Fellowship"],"award-info":[{"award-number":["Doctoral Fellowship"]}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["RHU CARMMA"],"award-info":[{"award-number":["RHU CARMMA"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Association Fran\u00e7aise contre les Myopathies","award":["MyoDR project #19100"],"award-info":[{"award-number":["MyoDR project #19100"]}]},{"name":"Association Fran\u00e7aise contre les Myopathies","award":["Pole Translamuscle project #19507"],"award-info":[{"award-number":["Pole Translamuscle project #19507"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2018,12,8]]},"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The role of interferons (IFN) in the pathophysiology of primary inflammatory and dysimmune myopathies (IDM) is increasingly investigated, notably because specific neutralisation approaches may constitute promising therapeutic tracks. In present work we analysed the muscular expression of specific IFN\u03b1\/\u03b2 and IFN\u03b3-stimulated genes in patients with various types of IDM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>39 patients with IDM with inclusion body myositis (IBM, n=9), dermatomyositis (DM, n=10), necrotising autoimmune myopathies (NAM, n=10) and antisynthetase myositis (ASM, n=10), and 10 controls were included. Quantification of expression levels of IFN\u03b3, ISG15, an IFN\u03b1\/\u03b2-inducible gene and of six IFN\u03b3-inducible genes (GBP2, HLA-DOB, HLA-DPB, CIITA, HLA-DRB and HLA-DMB) was performed on muscle biopsy samples.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>DM usually associated with strong type I IFN\u03b1\/\u03b2 signature, IBM and ASM with prominent type II IFN\u03b3 signature and NAM with neither type I nor type II IFN signature. Immunofluorescence study in ASM and IBM showed myofibre expression of major histocompatibility class 2 (MHC-2) and CIITA, confirming the induction of the IFN\u03b3 pathway. Furthermore, MHC-2-positive myofibres were observed in close proximity to CD8+ T cells which produce high levels of IFN\u03b3.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Distinct IFN signatures allow a more distinct segregation of IDMs and myofibre MHC-2 expression is a reliable biomarker of type II IFN signature.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2018-000811","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T06:02:06Z","timestamp":1551247326000},"page":"e000811","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":79,"title":["Distinct interferon signatures stratify inflammatory and dysimmune myopathies"],"prefix":"10.1136","volume":"5","author":[{"given":"Muriel","family":"Rigolet","sequence":"first","affiliation":[{"name":"IMRB, Inserm U955-Team 10, Paris Est-Creteil University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Hou","sequence":"additional","affiliation":[{"name":"IMRB, Inserm U955-Team 10, Paris Est-Creteil University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Baba Amer","sequence":"additional","affiliation":[{"name":"IMRB, Inserm U955-Team 10, Paris Est-Creteil University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Aouizerate","sequence":"additional","affiliation":[{"name":"IMRB, Inserm U955-Team 10, Paris Est-Creteil University, Paris, France"},{"name":"Reference Center for Neuromuscular Diseases, Henri Mondor University Hospitals, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Periou","sequence":"additional","affiliation":[{"name":"IMRB, Inserm U955-Team 10, Paris Est-Creteil University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain K","family":"Gherardi","sequence":"additional","affiliation":[{"name":"IMRB, Inserm U955-Team 10, Paris Est-Creteil University, Paris, France"},{"name":"Reference Center for Neuromuscular Diseases, Henri Mondor University Hospitals, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Lafuste","sequence":"additional","affiliation":[{"name":"IMRB, Inserm U955-Team 10, Paris Est-Creteil University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois J\u00e9r\u00f4me","family":"Authier","sequence":"additional","affiliation":[{"name":"IMRB, Inserm U955-Team 10, Paris Est-Creteil University, Paris, France"},{"name":"Reference Center for Neuromuscular Diseases, Henri Mondor University Hospitals, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"2025090313012840000_5.1.e000811.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2013.07.007"},{"key":"2025090313012840000_5.1.e000811.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2018.56"},{"key":"2025090313012840000_5.1.e000811.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202794"},{"key":"2025090313012840000_5.1.e000811.4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cyto.2014.10.012","article-title":"Interferons as components of the complex web of reactions sustaining inflammation in idiopathic inflammatory myopathies","volume":"74","author":"De Paepe","year":"2015","journal-title":"Cytokine"},{"key":"2025090313012840000_5.1.e000811.5","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20464"},{"key":"2025090313012840000_5.1.e000811.6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/art.40328","article-title":"Myogenic Progenitor Cells Exhibit Type I interferon-driven proangiogenic properties and molecular signature during juvenile dermatomyositis","volume":"70","author":"Gitiaux","year":"2018","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"2025090313012840000_5.1.e000811.7","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-014-0154-2"},{"key":"2025090313012840000_5.1.e000811.8","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000173991.74008.b0"},{"key":"2025090313012840000_5.1.e000811.9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ajpath.2015.11.010","article-title":"Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression","volume":"186","author":"Allenbach","year":"2016","journal-title":"Am J Pathol"},{"key":"2025090313012840000_5.1.e000811.10","first-page":"1871","article-title":"Inclusion body myositis","volume":"22","author":"Greenberg","year":"2016","journal-title":"Contin Minneap Minn"},{"key":"2025090313012840000_5.1.e000811.11","doi-asserted-by":"publisher","DOI":"10.1126\/science.8016643"},{"key":"2025090313012840000_5.1.e000811.12","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21805"},{"key":"2025090313012840000_5.1.e000811.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.24936"},{"key":"2025090313012840000_5.1.e000811.14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cyto.2014.11.026","article-title":"The role of type I interferons and other cytokines in dermatomyositis","volume":"73","author":"Arshanapalli","year":"2015","journal-title":"Cytokine"},{"key":"2025090313012840000_5.1.e000811.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-017-1731-9"},{"key":"2025090313012840000_5.1.e000811.16","doi-asserted-by":"crossref","unstructured":"Qian J , Wang C , Wang B , et al . The IFN-\u03b3\/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1\/PD-L1 therapy. J Neuroinflammation 2018;15.doi:10.1186\/s12974-018-1330-2","DOI":"10.1186\/s12974-018-1330-2"},{"key":"2025090313012840000_5.1.e000811.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)62513-8"},{"key":"2025090313012840000_5.1.e000811.18","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0b013e31827d7f16"},{"key":"2025090313012840000_5.1.e000811.19","doi-asserted-by":"crossref","unstructured":"Bergua C , Chiavelli H , Allenbach Y , et al . In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis 2018. doi: 10.1136\/annrheumdis-2018-213518. [Epub ahead of print 11 Oct 2018].doi:10.1136\/annrheumdis-2018-213518","DOI":"10.1136\/annrheumdis-2018-213518"},{"key":"2025090313012840000_5.1.e000811.20","doi-asserted-by":"crossref","unstructured":"Schoenborn JR , Wilson CB . Regulation of interferon\u2010\u03b3 during innate and adaptive immune responses. Advances in immunology. Elsevier, 2007: 41\u2013101.","DOI":"10.1016\/S0065-2776(07)96002-2"},{"key":"2025090313012840000_5.1.e000811.21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501902"},{"key":"2025090313012840000_5.1.e000811.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.23871"},{"key":"2025090313012840000_5.1.e000811.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2011.05.055"},{"key":"2025090313012840000_5.1.e000811.24","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004633"},{"key":"2025090313012840000_5.1.e000811.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew262"},{"key":"2025090313012840000_5.1.e000811.26","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1492-2"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2018-000811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:01:34Z","timestamp":1756929694000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2018-000811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,2,26]]},"published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1136\/rmdopen-2018-000811"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2018-000811","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}